Module 5: Management of Salicylate Toxicity

5.1 Initial Management Priorities

Stabilizing the Airway, Breathing and Circulation

The first priorities in caring for a patient with salicylate toxicity are stabilization of the airway, breathing and circulation. Assessment of mental status, respiratory pattern and depth, and hemodynamic stability guides the need for interventions.

Patients with severe CNS depression or respiratory compromise may require endotracheal intubation and mechanical ventilation to protect the airway. However, intubation comes with significant risks in salicylate poisoning. The apneic period leads to CO2 retention and worsening acidemia causing salicylates to rapidly redistribute into tissues and the CNS, precipitating clinical decline. Intubation should be reserved only for patients in extremis not responsive to other measures.

If intubation is absolutely necessary, 1-2 mEq/kg of sodium bicarbonate should be administered intravenously immediately before the procedure to buffer the acidosis. The ventilator settings then need to be adjusted to match or exceed the patient’s minute ventilation prior to intubation and maintain alkalemia. Frequent arterial blood gas monitoring is required to guide ventilator management and response.

Administering Supplemental Oxygen

Supplemental oxygen should be provided to hypoxic patients unable to maintain oxygen saturation above 94% with room air. The goal is to support oxygen delivery to vital organs until salicylate-induced metabolic derangements and pulmonary shunting can be corrected.

Intravenous Fluid Resuscitation

Intravenous fluid resuscitation helps restore volume deficits and maintain adequate renal perfusion for clearance. Patients are often dehydrated due to vomiting, hyperventilation, fever and increased insensible losses. Administering normal saline or lactated Ringer’s solution boluses of 500-1000 mL as needed achieves euvolemia. Fluid overload must be avoided.

Dextrose Administration

Intravenous dextrose should be administered despite normal glucose levels to reverse neuroglycopenia in the central nervous system. An initial bolus of 0.5-1 g/kg dextrose is recommended. This can prevent and treat altered mental status, seizures and coma attributable to cerebral hypoglycemia. An infusion may be needed for persistent CNS depression.

Electrolyte Repletion

Prompt correction of hypokalemia and hypocalcemia is vital. Potassium levels should be repleted to >4 mEq/L to enable alkaluria. Calcium gluconate treats hypocalcemia and reverses effects of bicarbonate chelation. Magnesium sulfate is indicated for documented hypomagnesemia to manage ventricular irritability.

---

5.2 Gastrointestinal Decontamination

Administering Activated Charcoal

Single or multiple dose activated charcoal can be administered within 1-2 hours of ingestion to reduce absorption of salicylate from the gut. Multi-dose regimens are preferred over single dose charcoal for large overdoses and sustained-release preparations. Each dose of charcoal can bind 100-300 mg of salicylate. The use of cathartics is no longer recommended given lack of enhanced efficacy and increased adverse effects.

Whole Bowel Irrigation

Whole bowel irrigation with polyethylene glycol electrolyte solution may have additional benefits compared to activated charcoal following massive ingestions, especially if an enteric coated or extended release product was ingested. It can help evacuate drug-containing bowel contents and combat delayed absorption from pharmacobezoars. However, aspiration risk with altered mental status warrants careful consideration.

---

5.3 Alkalinization Therapy

Sodium Bicarbonate Administration

Alkalinization with intravenous sodium bicarbonate remains a mainstay of therapy to increase renal clearance and prevent salicylate redistribution into tissues. An initial bolus of 1-2 mEq/kg is administered, followed by an infusion of 150 mEq sodium bicarbonate in 1 liter of D5W at 1.5-2 times maintenance infusion rate. The goal is to achieve a urine pH of 7.5-8.0 while maintaining the serum pH under 7.55.

Oral bicarbonate administration is contraindicated as it can increase absorption across the gastric mucosa. Overly rapid boluses can cause metabolic alkalosis. Prolonged therapy risks volume overload and electrolyte depletion. Common adverse effects include hypokalemia, hypocalcemia, hypoxemia, and paradoxical cerebral acidosis. Frequent monitoring helps minimize complications while achieving optimal alkalinization.

Monitoring Response to Alkalinization

Close monitoring is required to ensure adequate alkalinization while avoiding complications. Serum electrolytes, renal function, urine pH and serial salicylate concentrations should be evaluated every 2-4 hours initially. The frequency can be reduced as the patient stabilizes. The anion gap helps assess the degree of metabolic improvement.

Hypokalemia is a particular concern as it prevents achieving alkaluria and can cause dysrhythmias. Potassium repletion to 4-5 mEq/L is key. When the urinary pH is sustained above 7.5-8.0 and salicylate concentrations clearly decline in an asymptomatic patient, alkalinization therapy can be discontinued.

---

5.4 Extracorporeal Removal

Indications for Hemodialysis

Hemodialysis effectively removes salicylate and corrects acid-base disorders. It is indicated for concentrations exceeding 100 mg/dL in acute ingestions. Hemodialysis is also warranted in chronic toxicity with levels above 60-80 mg/dL depending on renal function. Regardless of the salicylate concentration, hemodialysis should be performed for serious signs like altered mental status, seizures, ARDS, kidney failure, circulatory collapse or clinical deterioration despite standard therapy.

Timing and Duration Considerations

The decision to start hemodialysis should be made early in the clinical course to prevent avoidable morbidity and mortality from delays. Appropriate consultation, coordination of hemodialysis access and patient transportation takes several hours. Clinical decline can be rapid, making it preferable to initiate plans for possible hemodialysis proactively.

Duration depends on the severity of toxicity. Hemodialysis is generally continued until clinical improvement is apparent, adequate clearance has been achieved and the concentration trends below 20 mg/dL. Longer or repeated sessions may be needed in massive ingestions if absorption from the gut continues. Close monitoring is maintained post-hemodialysis to ensure levels remain low as acidemia improves redistribution into tissues.

Alternative Extracorporeal Modalities

Hemodialysis is the preferred extracorporeal treatment based on efficacy for clearing salicylate and correcting acidemia. However, alternative modalities can be used when hemodialysis is not readily available. Sustained low-efficiency dialysis (SLED), continuous venovenous hemofiltration (CVVH), extracorporeal membrane oxygenation (ECMO) and exchange transfusion in pediatric patients are reported alternatives. The availability of these modalities depends on the care setting.

---

5.5 Summary of Key Pharmacologic Interventions

Sodium Bicarbonate

Mechanism: Alkalinizes blood and urine to ionize salicylate for enhanced clearance and reduced tissue redistribution.

Dose: 1-2 mEq/kg IV bolus, then 150 mEq in 1L D5W infusion.

Adverse Effects: Hypokalemia, hypocalcemia, hypoxemia, volume overload, paradoxical cerebral acidosis.

Activated Charcoal

Mechanism: Binds to salicylate in the gastrointestinal tract reducing absorption.

Dose: 1 g/kg PO every 2-4 hours for several doses.

Adverse Effects: Vomiting, constipation, aspiration pneumonia.

Dextrose

Mechanism: Reverses neuroglycopenia by providing substrate for glycolysis despite normal serum glucose.

Dose: 0.5-1 g/kg IV bolus, then infusion as needed.

Adverse Effects: Hyperglycemia, phlebitis, hypokalemia.

---

5.6 Disposition and Follow Up

Patients warrant admission for at least 24 hours of observation after acute ingestion to ensure concentrations remain low and no clinical deterioration occurs as absorption continues. Discharge is appropriate once the patient is asymptomatic, salicylate levels clearly downtrend, and psychiatric concerns have been addressed.

Following discharge, outpatient follow up should be arranged to confirm complete resolution, provide toxicity education and limit future access to salicylates in high risk patients. After significant toxicity, survivors should avoid or limit salicylate use given susceptibility to adverse reactions.

Overall, managing salicylate toxicity requires meticulous monitoring, tailored supportive care, enhanced elimination techniques and targeted pharmacologic interventions. An interdisciplinary approach with pharmacy, nephrology and toxicology guidance is ideal to deliver effective treatment and optimize patient outcomes.